All patients achieved a significant reduction in TSC-RAML volume over the first 6 months of induction treatment, and maintained a stable TSC-RAML volume during the low-dose maintenance period without any evidence of target AML lesion growth or progression. Here, TSC1 is linked to acute myeloid leukemia.